Full Text View
Tabular View
No Study Results Posted
Related Studies
Novel Hemostatic Cardiac Risk Factors in Framingham
This study has been completed.
First Received: May 25, 2000   Last Updated: June 23, 2005   History of Changes
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT00005356
  Purpose

To investigate hemostatic variables in relation to cardiovascular risk in the Framingham Offspring Study cohort.


Condition
Cardiovascular Diseases
Heart Diseases
Death, Sudden, Cardiac
Myocardial Infarction
Thrombosis
Atherosclerosis
Carotid Artery Diseases

MedlinePlus related topics: Cardiac Arrest Carotid Artery Disease Heart Attack Heart Diseases
U.S. FDA Resources
Study Type: Observational
Study Design: Natural History

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: July 1994
Estimated Study Completion Date: May 1998
Detailed Description:

BACKGROUND:

Elevation of platelet reactivity plasminogen activator inhibitor, fibrinogen, von Willebrand's factor, and factor VII have been reported to increase myocardial infarction risk. Myocardial infarction and sudden cardiac death are more frequent in the morning when platelet activity is increased and fibrinolysis is decreased. Reduction of recurrent myocardial infarction by aspirin and coumadin suggests causal roles for platelet activity and coagulation. Increases in viscosity and decreases in anti-thrombin III and Protein C have been linked with increased thrombosis. Despite these findings, a coherent picture of these disparate hemostatic indices as cardiac risk factors has yet to emerge.

DESIGN NARRATIVE:

Platelet reactivty, plasminogen activatator inhibitor, fibrinogen, von Willebrand's factor, factor VII, and other hemostatic risk factors were measured in all 4,000 subjects of the Framingham Offspring Study. The data were combined with the regularly collected Framingham data to: determine the relationships between hemostatic factors and carotid atherosclerosis as assessed by ultrasound; determine the relationship between hemostatic factors and the traditional cardiac risk factors; and determine if hemostatic risk factors independently predict myocardial infarction and cardiac death.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

No eligibility criteria

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005356

Sponsors and Collaborators
Investigators
Investigator: Geoffrey Tofler Beth Israel Deaconess Medical Center
  More Information

Publications:
Study ID Numbers: 4242
Study First Received: May 25, 2000
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00005356     History of Changes
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Atherosclerosis
Arterial Occlusive Diseases
Death
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Central Nervous System Diseases
Heart Arrest
Ischemia
Arteriosclerosis
Brain Diseases
Cerebrovascular Disorders
Hemostatics
Thrombosis
Embolism and Thrombosis
Necrosis
Embolism
Death, Sudden
Death, Sudden, Cardiac
Carotid Artery Diseases
Infarction
Myocardial Infarction

Additional relevant MeSH terms:
Atherosclerosis
Arterial Occlusive Diseases
Death
Heart Diseases
Myocardial Ischemia
Nervous System Diseases
Vascular Diseases
Central Nervous System Diseases
Heart Arrest
Ischemia
Arteriosclerosis
Brain Diseases
Cerebrovascular Disorders
Thrombosis
Embolism and Thrombosis
Necrosis
Pathologic Processes
Death, Sudden
Cardiovascular Diseases
Death, Sudden, Cardiac
Carotid Artery Diseases
Infarction
Myocardial Infarction

ClinicalTrials.gov processed this record on May 07, 2009